Shanghai-based Antengene (SEHK: 6996) has announced that the Malaysian medicines regulator has approved Xpovio (selinexor) for the treatment of multiple myeloma.
The nod allows Xpovio to be used, in combination with bortezomib and dexamethasone, for people who have received at least one prior therapy.
Additionally, it can be used with dexamethasone for those who have received at least four prior treatments and whose disease is resistant to multiple drug classes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze